Actos (Pioglitazone) Cost in Illinois 2026: Prices, Insurance, and Savings

What Does Pioglitazone Actually Cost in Illinois?

The average cash price for generic pioglitazone across Illinois retail pharmacies in 2026 sits around $15 per month for a 30-day supply, regardless of whether the prescribed dose is 15 mg, 30 mg, or 45 mg. Brand-name Actos carries a manufacturer list price of approximately $60 per month from Takeda, though very few patients pay this figure out of pocket given the wide availability of generics.

Pioglitazone lost patent exclusivity in 2012, and that single event reshaped the drug's cost profile more than any other factor. Before generic entry, Actos was one of the top-selling diabetes drugs in the United States, generating over $3.5 billion in annual U.S. revenue at its peak 1. Today, multiple manufacturers produce generic pioglitazone tablets, which means pharmacies compete on acquisition cost.

Prices vary by pharmacy. At large Illinois chain pharmacies (CVS, Walgreens, Walmart), a 30-day supply typically ranges from $10 to $20 without insurance. Independent pharmacies may charge slightly more. Warehouse clubs like Costco and Sam's Club in Illinois often list pioglitazone below $10 for members. GoodRx and RxSaver coupons can push the price toward the lower end of that range, though these discount aggregators are not insurance and do not count toward deductibles.

The practical bottom line: pioglitazone is one of the least expensive branded-class diabetes medications available in Illinois. It costs a fraction of what newer agents like SGLT2 inhibitors ($400 to $600 per month) or GLP-1 receptor agonists ($800 to $1,200+ per month) run at retail 2.

Illinois Medicaid Coverage for Pioglitazone

Illinois Medicaid, administered through the state's managed care organizations (MCOs), covers pioglitazone with prior authorization. The prior authorization requirement exists because the state's preferred drug list (PDL) generally steers first-line therapy toward metformin, and prescribers must document either metformin intolerance, a contraindication, or clinical need for a thiazolidinedione before Medicaid approves pioglitazone.

The prior authorization process in Illinois typically takes 24 to 72 hours when submitted electronically through the CoverMyMeds or SureScripts platforms. Prescribers should include the patient's A1C, a record of prior metformin trial (or contraindication such as an eGFR below 30 mL/min/1.73 m²), and the clinical rationale.

For patients with Medicaid coverage who receive approval, copays are minimal. Illinois caps Medicaid pharmacy copays at $3.90 for generic drugs under federal guidelines set by the Centers for Medicare & Medicaid Services. Some MCO plans waive copays entirely for diabetes medications. Patients enrolled in the state's Medical Assistance program who have questions about their specific plan formulary should call the number on the back of their MCO card or contact the Illinois Department of Healthcare and Family Services (HFS) at 877-782-5565.

The American Diabetes Association's 2024 Standards of Care list pioglitazone as a second- or third-line option after metformin, particularly for patients with insulin resistance, NAFLD/NASH, or those who cannot tolerate or afford newer agents 3.

How Insurance Plans in Illinois Handle Pioglitazone

Most commercial insurance plans in Illinois place generic pioglitazone on Tier 1 (preferred generic), which means the lowest copay bracket. Typical Tier 1 copays on Illinois employer-sponsored plans range from $0 to $15 per 30-day fill. Brand Actos, if dispensed instead of the generic, falls on Tier 2 or Tier 3 depending on the plan, with copays of $30 to $75.

Blue Cross Blue Shield of Illinois (BCBSIL), the state's largest commercial insurer, lists generic pioglitazone on its standard formulary without prior authorization for most plan types. UnitedHealthcare and Aetna plans available on the Illinois ACA marketplace similarly cover generic pioglitazone at Tier 1.

Medicare Part D plans in Illinois also cover pioglitazone. Under the 2025 Inflation Reduction Act cap (which continues into 2026), Medicare Part D out-of-pocket costs for all covered drugs are capped at $2,000 per year. Since pioglitazone costs well under that threshold, most Medicare patients in Illinois pay a $0 to $10 copay per month for the drug.

One detail worth noting for patients switching between plans during Open Enrollment: even though pioglitazone is nearly universally covered, the specific quantity limits may differ. Some plans authorize a 90-day supply through mail-order at a lower per-unit cost. Patients filling through Express Scripts, OptumRx, or CVS Caremark mail-order programs in Illinois can often get a 90-day supply for $10 to $25 total.

Compounded Pioglitazone in Illinois: Legality and Access

Compounded pioglitazone is legal in Illinois through 503A-licensed compounding pharmacies. Section 503A of the Federal Food, Drug, and Cosmetic Act permits licensed pharmacies to compound medications based on a valid patient-specific prescription when a clinical need exists 4.

Why would anyone compound pioglitazone when a cheap generic tablet already exists? A few clinical scenarios drive this. Some patients need a liquid suspension because they cannot swallow tablets (post-bariatric surgery, dysphagia, pediatric off-label use). Others require a non-standard dose, such as 7.5 mg or 22.5 mg, that is not commercially available. Compounding fills those gaps.

Illinois regulates 503A pharmacies through the Illinois Department of Financial and Professional Regulation (IDFPR). Pharmacies must hold a valid compounding license, follow USP 795 standards for non-sterile compounding, and maintain batch records. Patients can verify a pharmacy's license status through the IDFPR online lookup tool.

Cost for compounded pioglitazone varies based on the pharmacy, formulation, and dose. Some 503A pharmacies in Illinois have quoted prices as low as $0 for simple pioglitazone capsule reformulations when bundled with a consultation or membership model, though standalone compounded preparations typically range from $15 to $40 per month.

Patients should be aware that compounded medications are not FDA-approved finished products. They do not undergo the same bioequivalence testing as generic tablets. The FDA recommends using commercially available products when they meet the patient's clinical needs and reserving compounding for situations where no suitable commercial alternative exists.

Pioglitazone via Telehealth in Illinois

Telehealth prescribing of pioglitazone is fully legal in Illinois. The state's Telehealth Act (Public Act 102-0104), signed into law in 2021 and extended through subsequent legislation, permits Illinois-licensed prescribers to evaluate patients and write prescriptions via synchronous audio-video visits. No in-person visit is required before initiating pioglitazone, provided the prescriber establishes an adequate patient-provider relationship during the telehealth encounter.

For patients in rural counties (southern Illinois, western Illinois) where endocrinology access is limited, telehealth significantly reduces barriers. A 2023 analysis published in Diabetes Care found that telehealth-managed diabetes patients achieved comparable A1C reductions to in-person cohorts (mean difference 0.05%, 95% CI -0.12 to 0.22), supporting the clinical equivalence of remote diabetes management 5.

Several telehealth platforms operating in Illinois, including HealthRX, can prescribe pioglitazone after an online evaluation. The prescription is then sent to the patient's preferred Illinois pharmacy. Patients should confirm their chosen pharmacy stocks pioglitazone, though given how common the drug is, stockouts are rare.

Discount Programs and Savings Cards

Several pathways can reduce pioglitazone costs below the already-low retail price in Illinois.

Manufacturer savings: Takeda, the original manufacturer of brand Actos, previously offered a savings card, though the program has been scaled back significantly since generic entry. As of 2026, no active Takeda-branded Actos savings card is widely available for new enrollees. Patients searching for "Takeda Actos savings card" online should verify current program status directly on Takeda's website, as expired program pages still circulate.

Pharmacy discount programs: Walmart's $4 generic list includes pioglitazone in many markets, though pricing varies by location. Costco's member pricing and Mark Cuban's Cost Plus Drugs (costplusdrugs.com) offer pioglitazone at near-acquisition cost. Cost Plus Drugs listed pioglitazone 45 mg (30 tablets) at approximately $5 to $8 including shipping as of early 2026.

Free/low-cost coupon aggregators: GoodRx, RxSaver, and SingleCare all show Illinois-specific pioglitazone pricing. These platforms negotiate discounted rates with pharmacy benefit managers and pass the savings through at the point of sale. A GoodRx coupon at a Chicago-area CVS or Walgreens typically brings pioglitazone to $8 to $14 per month.

Patient assistance programs: NeedyMeds (needymeds.org) and RxAssist maintain directories of patient assistance programs for diabetes medications. While pioglitazone's low generic cost means fewer patients qualify for formal assistance, patients with no insurance and limited income should check these resources.

340B pricing: Federally Qualified Health Centers (FQHCs) and certain Illinois hospitals participate in the 340B Drug Pricing Program, which allows eligible facilities to purchase pioglitazone at deeply discounted rates and pass savings to qualifying patients. Illinois has over 50 FQHC sites, concentrated in Chicago, Rockford, Springfield, and East St. Louis.

Clinical Context: Why Pioglitazone Still Matters

Pioglitazone belongs to the thiazolidinedione (TZD) drug class. It works by activating PPAR-gamma receptors, which increases insulin sensitivity in adipose tissue, skeletal muscle, and the liver. The FDA approved pioglitazone for type 2 diabetes in 1999 6.

Despite being overshadowed by newer drug classes, pioglitazone retains clinical relevance for several reasons. The PIVENS trial (Pioglitazone versus Vitamin E versus Placebo for the Treatment of Nondiabetic Patients with Nonalcoholic Steatohepatitis), published in the New England Journal of Medicine in 2010, demonstrated that pioglitazone 30 mg daily significantly improved hepatic steatosis, inflammation, and the composite NASH activity score compared to placebo (reduction in NAS score of 2 or more: 47% pioglitazone vs. 21% placebo, P<0.001) 7.

The AASLD's 2023 practice guidance on NAFLD/NASH states: "Pioglitazone can be used to treat biopsy-proven NASH in patients with and without type 2 diabetes" 8. This recommendation gives pioglitazone a role that few other inexpensive generics can fill in the NASH treatment space, where the only FDA-approved alternative (resmetirom/Rezdiffra) costs significantly more.

A meta-analysis of 26 randomized controlled trials (N=3,314 patients) published in The Lancet Diabetes & Endocrinology found that pioglitazone reduced the risk of major adverse cardiovascular events by 17% (RR 0.83, 95% CI 0.72 to 0.97) in patients with insulin resistance or type 2 diabetes 9. Dr. Ralph DeFronzo of the University of Texas Health Science Center has stated, "Pioglitazone is the only diabetes drug proven to reduce cardiovascular events, improve NASH histology, and lower stroke risk, all at a cost that makes it accessible to nearly every patient."

The drug does carry well-documented risks. Weight gain (mean 2 to 4 kg over 12 months), fluid retention, and increased fracture risk (particularly in postmenopausal women) are the primary concerns 10. Pioglitazone is contraindicated in NYHA Class III or IV heart failure. Prescribers in Illinois and elsewhere should screen for these contraindications before initiating therapy.

Comparing Pioglitazone to Other Diabetes Drug Costs in Illinois

To put pioglitazone's $15-per-month price in perspective, here is how other common diabetes medications compare at Illinois retail pharmacies in 2026:

Metformin 1,000 mg twice daily runs approximately $4 to $10 per month (generic). Glipizide 10 mg costs $4 to $8. These are the only diabetes drugs priced similarly to pioglitazone.

Moving up the cost ladder: empagliflozin (Jardiance) lists at $550 to $620 per month before insurance. Semaglutide oral (Rybelsus) runs $900 to $1,050 per month at list. Injectable semaglutide (Ozempic) lists at approximately $935 per month 11. Tirzepatide (Mounjaro) lists at roughly $1,023 per month. Even with insurance, these newer agents carry $25 to $150 monthly copays on most commercial plans.

For Illinois patients managing type 2 diabetes on a budget, pioglitazone remains one of a small handful of evidence-based options that cost less than a single restaurant meal per month. The American Association of Clinical Endocrinology (AACE) 2023 consensus statement acknowledges cost as a legitimate clinical variable: "Access and affordability should be considered when selecting glucose-lowering therapy, particularly for patients facing financial barriers to medication adherence" 12.

How to Get the Lowest Price on Pioglitazone in Illinois

Start by asking your prescriber to write for generic pioglitazone (not brand Actos). Every pharmacy in Illinois is required by state law to offer generic substitution unless the prescriber writes "DAW" (dispense as written) on the prescription. Next, compare prices across at least three pharmacies using GoodRx or RxSaver. If the cash price with a coupon is lower than your insurance copay, pay cash. There is no rule requiring you to use insurance for every fill.

For the absolute lowest cost, check Cost Plus Drugs (mail order), Walmart's $4 list (in-store), or a local 340B-eligible FQHC pharmacy. Patients with Illinois Medicaid should use their benefit, as the copay will be $0 to $3.90. Medicare Part D enrollees should use their plan's preferred pharmacy network to minimize cost-sharing.

Pioglitazone 30 mg once daily is the most commonly prescribed dose for both type 2 diabetes and off-label NASH use, based on the PIVENS trial protocol 7. Most Illinois prescribers initiate at 15 mg and titrate to 30 mg after 4 to 8 weeks if tolerated.